17:35 , Mar 23, 2018 |  BC Week In Review  |  Company News

Lundbeck snags PD play Prexton

H. Lundbeck A/S (CSE:LUN) will acquire Prexton Therapeutics B.V. (Oss, the Netherlands) for €100 million ($123.4 million) up front. Shareholders in the neurology company will also be eligible for up to €805 million ($993.2 million)...
10:47 , Mar 16, 2018 |  BC Extra  |  Company News

Lundbeck snags PD play Prexton

H. Lundbeck A/S (CSE:LUN) will acquire Prexton Therapeutics B.V. (Oss, the Netherlands) for €100 million ($123.4 million) up front. Shareholders in the neurology company will also be eligible for up to €805 million ($993.2 million)...
00:58 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Prexton begins Phase II of foliglurax for PD

Prexton Therapeutics S.A. (Geneva, Switzerland) began the double-blind, placebo-controlled, European Phase II AMBLED trial to evaluate 10 and 30 mg doses of oral foliglurax (PXT002331) for 28 days in 165 patients with Parkinson’s disease (PD)...
17:27 , Feb 7, 2017 |  BC Extra  |  Financial News

Prexton raises EUR 29M in series B round

Neurology company Prexton Therapeutics S.A. (Plan-les-Ouates, Switzerland) raised EUR 29 million ($31.2 million) in a series B round co-led by Forbion Capital Partners and Seroba Life Sciences. Also participating were prior investors MS Ventures, Ysios...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

PXT002331: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in 64 healthy volunteers showed that single and multiple ascending doses of oral PXT002331 were well tolerated. In 2013, Prexton exercised an option from Domain for an exclusive,...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

MGluR4 PAM: Phase I started

Prexton began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending doses of oral PXT002331 in about 72 healthy volunteers. In 2013, Prexton exercised an option from Domain for an exclusive,...
08:00 , Mar 2, 2015 |  BioCentury  |  Finance

Prexton's PD inflection

Prexton Therapeutics S.A. became the first spinout from Merck Serono S.A.'s Entrepreneur Partnership Program to raise follow-on funding with the close of its €8.7 million ($9.9 million) series A round last week. The cash will...
03:03 , Feb 25, 2015 |  BC Extra  |  Financial News

CNS play Prexton closes A round

Prexton Therapeutics S.A. (Plan les Ouates, Switzerland) raised EUR 8.7 million ($9.9 million) in a series A round co-led by new investors Sunstone Capital and Ysios Capital. Existing investor MS Ventures also participated. Prexton plans...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...